Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Antiphospholipid syndrome (APS) is frequently coexisting with systemic lupus erythematosus (SLE) and the knowledge on its genetic background is essential. The objective of this work was to assess distribution of human leukocyte antigen (HLA)-DRB1 alleles in patients with APS with or without SLE in the context of Polish population data. The study was performed in a group of 112 patients with APS and healthy subjects to assess the distribution of HLA-DRB1 alleles in patients with APS and their association with clinical characteristics of patients with APS-antiphospholipid antibodies (aPLs) presence and disease activity/damage indexes. The distribution of HLA-DRB1 alleles showed significant differences between patients with APS and healthy subjects. Allelic variant HLA-DRB1 1.15 was identified as risk alleles for APS observed in patients with APS (odds ratio (OR): 2.06 (1.27, 3.23), =0, 004), while HLA-DRB1 1.07 showed significant protective association (OR: 0.37 (0.14-0.76), =0, 006). In subgroup of patients with coexisting SLE allelic variants above were not identified as risk or protective, while protective association was described for HLA-DRB1 01, but not for patients in primary APS group. Presence of antibodies anti- -glycoprotein-I (a GPI) IgA and against domain 1, anti-phosphatidylserine/prothrombin (aPS/PT) and anticardiolipin antibody (aCL) IgA all the antibodies which were negatively associated with HLA-DRB1 15.01 carriers, what was reported for the first time may be suitable in discussion about value of these antibodies in practice and scientific research. This study clearly shows that primary APS has a distinct HLA-DRB1 associations as compared with SLE with a strong positive association with HLA-DRB1 15.01 allele and a protective association with HLA-DRB1 07.01.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11957857PMC
http://dx.doi.org/10.1155/jimr/2827348DOI Listing

Publication Analysis

Top Keywords

patients aps
20
hla-drb1 alleles
16
distribution hla-drb1
12
alleles patients
12
protective association
12
hla-drb1
10
patients
9
aps
9
antiphospholipid syndrome
8
assess distribution
8

Similar Publications

Genetic factors associated with the co-occurrence of endometriosis with antiphospholipid syndrome (Review).

Exp Ther Med

October 2025

Section of Molecular Pathology and Human Genetics, Department of Internal Medicine, School of Medicine, University of Crete, 71003 Heraklion, Greece.

Immune-related factors may serve an important role in the development of endometriosis, considering the occurrence of substantial abnormalities in the immune system of women with endometriosis, including reduced T-cell reactivity and natural killer cell cytotoxicity, as well as increased numbers and activation of peritoneal macrophages. Moreover, women suffering from endometriosis are at a higher risk for developing various autoimmune diseases as comorbidities of endometriosis. Recent epidemiological data demonstrate that patients with endometriosis have a significantly higher risk (2.

View Article and Find Full Text PDF

Background: Antiphospholipid syndrome (APS) is a major immune-related disorder that leads to adverse pregnancy outcomes (APO), including recurrent miscarriage, placental abruption, preterm birth, and fetal growth restriction. Antiphospholipid antibodies (aPLs), particularly anticardiolipin antibodies (aCL), anti-β2-glycoprotein I antibodies (aβ2GP1), and lupus anticoagulant (LA), are considered key biomarkers for APS and are closely associated with adverse pregnancy outcomes. This is a prospective observational cohort study to use machine learning model to predict adverse pregnancy outcomes in APS patients using early pregnancy aPL levels and clinical features.

View Article and Find Full Text PDF

Introduction: Electronic health records can be used to create high-quality databases if data are structured and well-registered, which is the case for most perioperative data in the Capital and Zealand Regions of Denmark. We present the purpose and development of the AI and Automation in Anaesthesia (TRIPLE-A) database-a platform designed for epidemiology, prediction, quality control, and automated research data collection.

Methods: Data collection from the electronic medical record (EPIC Systems Corporation, WI, USA) was approved by the Capital Region, Denmark, and ethical approval was waived.

View Article and Find Full Text PDF

CAR-T cell therapy has been proven effective in various autoimmune diseases, with most studies utilizing lentiviral-transduced CAR-T cells. In recent years, retroviral vector-transduced CAR-T cells-characterized by a high positivity rate, stable cell lines, and lower plasmid requirements-have attracted increasing attention. This article presents a complex case of a patient with SLE combined with APS and TBIRS.

View Article and Find Full Text PDF

Antiphospholipid antibody syndrome (APS) is an autoimmune disorder characterized by arterial and venous thrombosis, pregnancy-related complications, and persistent antiphospholipid antibodies. These manifestations pose significant risks to patient health and reproductive outcomes. Initially regarded as a manifestation of systemic lupus erythematosus (SLE), APS exhibits a close epidemiological association with SLE, occurring at significantly higher incidence in SLE patients.

View Article and Find Full Text PDF